Bamlanivimab
巴尼韦单抗
Report date: 2023/03/29 13:05:16
Base Information
Drug NameBamlanivimab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[13]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbCellera Biologics IncEli Lilly And Company
China Registration ClassN/A
Develop Information
Active CompaniesEli Lilly And CompanyAbCellera Biologics Inc
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksDrugBank